reports
SIGA Reports Financial Results for Three Months Ended March 31, 2025
SIGA Reports Financial Results for Three Months Ended March 31, 2025 Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. “SIGA has carried its momentum from 2024 into 2025, achieving stea...
SIGA to Host Business Update Call on May 8, 2025 Following Release of ...
SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 8, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relatio...
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Declares Special Cash Dividend of $0.60 Per Share NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock. This represents the fourth straight year of a special cash dividend. The amount of the dividend declared is consistent with the level of the dividend declared in March 2024. The dividend is payable on May 15, 2025, to shareholders of record at the close of business on April 29,...
SIGA Appoints Retired General John M. Keane to its Board of Directors
SIGA Appoints Retired General John M. Keane to its Board of Directors General Keane brings significant expertise in national security and biodefense preparedness NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John “Jack” Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief...
SIGA Reports Financial Results for Three and Twelve Months Ended Decem...
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024 Increased Product Sales to $133 Million in 2024Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million, Respectively, in 2024Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2024. “2024 was a year of strong financial performance and operational execution for SIG...
SIGA to Host Business Update Call on March 11, 2025 Following Release ...
SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 11, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's web...
- Jonathan Moreland
XNCR XENCOR INC.
RLI RLI CORP.
PBF PBF ENERGY INC. CLASS A
ORRF ORRSTOWN FINANCIAL SERVICES INC.
NEOG NEOGEN CORPORATION
MKL MARKEL CORPORATION
LAKE LAKELAND INDUSTRIES INC.
JBLU JETBLUE AIRWAYS CORPORATION
EL ESTEE LAUDER COMPANIES INC. CLASS A
CTSO CYTOSORBENTS
BUSE FIRST BUSEY CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
CBFV CB FINANCIAL SERVICES INC.
MUR MURPHY OIL CORPORATION
OLN OLIN CORPORATION
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
KALV KALVISTA PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
NWFL INC.
FRAF NORWOOD FINANCIAL CORP.
ETST FRANKLIN FINANCIAL SERVICES CO.
LOOP EARTH SCIENCE TECH
ANIX LOOP INDUSTRIES
MFON ANIXA BIOSCIENCES
PNTG MOBIVITY HOLDINGS CORP.
ZYME PENNANT GROUP
PLCE ZYMEWORKS INC.
ALLY THE CHILDREN'S PLACE RETAIL STORES
IMNM INC.
CTOS GMAC LLC
IBRX IMMUNOME
BHRB CUSTOM TRUCK ONE SOURCE
VGAS INC.
TLSI IMMUNITYBIO INC
TKO BURKE & HERBERT BANK & TR/VA
PCSA VERDE CLEAN FUELS INC
PROP TRISALUS LIFE SCIENCES INC
MIO TKO GROUP HOLDINGS
MXF INC.
SUNS PROCESSA PHARMACEUTICALS INC
BATRK PRAIRIE OPERATING CO.
MYCB PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
THE MEXICO FUND
INC.
SUNRISE REALTY TRUST
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
- Jonathan Moreland
RLI RLI CORP.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
ASA ASA
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
ETST INC.
LOOP EARTH SCIENCE TECH
FUND LOOP INDUSTRIES
ANIX ROYCE FOCUS TRUST
LBSRD INC.
ETON ANIXA BIOSCIENCES
GRX LIBERTY STAR URANIUM & METALS
MFON ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ZYME MOBIVITY HOLDINGS CORP.
ALLY PENNANT GROUP
ENX ZYMEWORKS INC.
IBRX GMAC LLC
ACXP EATON VANCE NEW YORK MUNICIPAL BOND FUND
CVI IMMUNITYBIO INC
TLSI ACURX PHARMACEUTICALS INC
PCSA CVR ENERGY
PROP INC.
AVDL TRISALUS LIFE SCIENCES INC
MIO PROCESSA PHARMACEUTICALS INC
MXF PRAIRIE OPERATING CO.
SUNS AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
TXO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
AMST THE MEXICO FUND
WHLM INC.
IBIO SUNRISE REALTY TRUST
SDHY MORNINGSTAR PARTNERS
BATRK L.P.
MYCB AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
- Jonathan Moreland
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
CDXS CODEXIS
ASA ASA
ADC AGREE REALTY CORPORATION
WVE WAVE LIFE SCIENCES
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
ZIVO INC.
ETST ZIVO BIOSCIENCE
FUND INC.
ANIX EARTH SCIENCE TECH
LBSRD ROYCE FOCUS TRUST
ETON INC.
GRX ANIXA BIOSCIENCES
MCFT LIBERTY STAR URANIUM & METALS
PGNY ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
PRLD PENNANT GROUP
NVCT DELCATH SYSTEMS
ANEB EATON VANCE NEW YORK MUNICIPAL BOND FUND
IBRX PRELUDE THERAPEUTICS
BHVN NUVECTIS PHARMA INC
ACXP ANEBULO PHARMACEUTICALS INC
BUKS IMMUNITYBIO INC
GLSI BIOHAVEN LTD
MEGI ACURX PHARMACEUTICALS INC
CVI BUTLER NATIONAL CORP
SRFM GREENWICH LIFESCIENCES INC
OCX MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
AVDL CVR ENERGY
MXF INC.
TXO SURF AIR MOBILITY INC.
TTGT ONCOCYTE CORPORATION
AMST AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
WHLM THE MEXICO FUND
IBIO INC.
SDHY MORNINGSTAR PARTNERS
BATRK L.P.
MYCB TECHTARGET INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
- Jonathan Moreland
Credit Suisse Asset Management Income Fund Inc: 1 director
A director at Credit Suisse Asset Management Income Fund Inc bought 40,766 shares at 2.920USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxvi...
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor to supply TEPOXX to Japan’s national stockpileComprehensive data package demonstrates strong safety profile and robust preclinical efficacy NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirim...
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of...
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults affirm tecovirimat’s strong safety profileEfficacy in patients with more severe disease not assessed in study NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analy...
- Sean Conroy
SIGA Technologies - Strong order book moving into Q424
SIGA Technologies reported revenues of $10m in Q324, attributed primarily to deliveries under the $112.5m BARDA option, exercised in July 2024. Backed by a strong order book ($146m at end-Q324), the sales momentum has picked up pace in Q424 with another $51.2m and $8.5m of oral and IV TPOXX (IVT) delivered to the Strategic National Stockpile (SNS) in October 2024. We expect further deliveries in Q424 and early 2025 under the BARDA contract as well as the $9m US Department of Defense (DoD) order ...
SIGA Reports Financial Results for Three and Nine Months Ended Septemb...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024 Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectivelyReceived $122 Million of Procurement Orders from the U.S. Government in the Third QuarterCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2024. “Building on strong momentum,...
SIGA to Host Business Update Call on November 7 Following Release of T...
SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the I...
SIGA Enters into Exclusive License Agreement with Vanderbilt Universit...
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. Under the agreement, SIGA has exerc...
SIGA Announces Agreement to Supply TPOXX® in Morocco
SIGA Announces Agreement to Supply TPOXX® in Morocco NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement to supply TPOXX (tecovirimat) in Morocco. The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak. Tecovirimat is approved in the U.S., Canada, and the EU, and while...
- Sean Conroy
SIGA Technologies - TPOXX chalks up another DoD contract win
SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for a total of approximately $28m and adds to the already robust H224 orderbook of c $154m of outstanding TPOXX orders, following the July 2024 $112.5m option exercise from the Biomedical Advanced Research and Development Authority (BARDA) for oral TPOXX. While delivery timeline details are yet to be di...
SIGA Announces New Contract Awarded by U.S. Department of Defense for ...
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award fr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.